Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Treating younger MM patients: finding the optimal induction regimen

Joan Bladé • 17 May 2019
COMy 2019
Multiple Myeloma Bortezomib Carfilzomib Daratumumab Dexamethasone Lenalidomide

Joan Bladé, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, describes the current and future treatment regimens for the optimal induction of younger patients with multiple myeloma peritransplant. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Joan Bladé

2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals